Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This is a combination drug consisting of four active ingredients—fentanyl, morphine, paracetamol (acetaminophen), and tramadol. All four are analgesics but act via different mechanisms to provide multimodal pain relief. Fentanyl and morphine are potent opioid agonists primarily targeting the μ-opioid receptor to inhibit pain transmission in the central nervous system. Tramadol is a centrally acting synthetic opioid that not only acts as a μ-opioid receptor agonist but also inhibits serotonin and norepinephrine reuptake, contributing additional analgesic effects[1][6]. Paracetamol is an analgesic and antipyretic agent with a mechanism believed to involve inhibition of prostaglandin synthesis in the central nervous system. The combination aims for synergistic pain control by leveraging both opioid and non-opioid pathways.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on fentanyl + morphine + paracetamol + tramadol.